The company has launched a medicinal chemistry effort to develop kinetin analogs that can activate PINK1, a protein linked to Parkinson's disease. Mitokinin plans to use these analogs to treat Parkinson's disease by developing optimized variants. The company's neo-substrates are kinase-targeted and intended to treat neurodegenerative and mitochondrial diseases. These substrates serve as alternative phospho-donors for specific kinases, boosting the activity of the active-form kinase and reducing the risk of off-targets. This enables physicians to offer a substrate-specific treatment for patients.